Latest From Vaxon Biotech
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Recent executive-level company changes and promotions in the biopharma, medical device, and diagnostics industries.
Both AcelRx and Sagent turn to interim CEOs during company transitions.
The biotech has a three-pronged strategy to double revenues by 2017: continue to expand core multiple myeloma product Revlimid, bring new blockbusters online, and develop its early stage pipeline through deals.
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Vaxon Biotech
- Senior Management
Kostas Kosmatopoulos, MD, PhD, CEO
Nadege Le Roux, PhD, MSc, Dir., Drug Dev.
- Contact Info
Phone: (33) 160789210
2 rue Gaston Cremieux
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.